AAAAAA

   
Results: 1-7 |
Results: 7
SH3GLB, a new endophilin-related protein family featuring an SH3 domain
Authors: Pierrat, B Simonen, M Cueto, M Mestan, J Ferrigno, P Heim, J
Citation: B. Pierrat et al., SH3GLB, a new endophilin-related protein family featuring an SH3 domain, GENOMICS, 71(2), 2001, pp. 222-234
Skp2 is oncogenic and overexpressed in human cancers
Authors: Gstaiger, M Jordan, R Lim, M Catzavelos, C Mestan, J Slingerland, J Krek, W
Citation: M. Gstaiger et al., Skp2 is oncogenic and overexpressed in human cancers, P NAS US, 98(9), 2001, pp. 5043-5048
Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and invitro
Authors: Tille, JC Wood, J Mandriota, SJ Schnell, C Ferrari, S Mestan, J Zhu, Z Witte, L Pepper, MS
Citation: Jc. Tille et al., Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and invitro, J PHARM EXP, 299(3), 2001, pp. 1073-1085
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis (vol 43, pg 2316, 2000)
Authors: Bold, G Altmann, KH Frei, J Lang, M Manley, PW Traxler, P Wietfeld, B Bruggen, J Buchdunger, E Cozens, R Ferrari, S Furet, P Hofmann, F Martiny-Baron, G Mestan, J Rosel, J Sills, M Stover, D Acemoglu, F Boss, E Emmenegger, R Lasser, L Masso, E Roth, R Schlachter, C Vetterli, W Wyss, D Wood, JM
Citation: G. Bold et al., New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis (vol 43, pg 2316, 2000), J MED CHEM, 43(16), 2000, pp. 3200-3200
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
Authors: Bold, G Altmann, KH Frei, J Lang, M Manley, PW Traxler, P Wietfeld, B Bruggen, J Buchdunger, E Cozens, R Ferrari, S Furet, P Hofmann, F Martiny-Baron, G Mestan, J Rosel, J Sills, M Stover, D Acemoglu, F Boss, E Emmenegger, R Lasser, L Masso, E Roth, R Schlachter, C Vetterli, W Wyss, D Wood, JM
Citation: G. Bold et al., New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis, J MED CHEM, 43(12), 2000, pp. 2310-2323
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
Authors: Wood, JM Bold, G Buchdunger, E Cozens, R Ferrari, S Frei, J Hofmann, F Mestan, J Mett, H O'Reilly, T Persohn, E Rosel, J Schnell, C Stover, D Theuer, A Towbin, H Wenger, F Woods-Cook, K Menrad, A Siemeister, G Schirner, M Thierauch, KH Schneider, MR Drevs, J Martiny-Baron, G Totzke, F Marme, D
Citation: Jm. Wood et al., PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, CANCER RES, 60(8), 2000, pp. 2178-2189
Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent
Authors: Fabbro, D Buchdunger, E Wood, J Mestan, J Hofmann, F Ferrari, S Mett, H O'Reilly, T Meyer, T
Citation: D. Fabbro et al., Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent, PHARM THERA, 82(2-3), 1999, pp. 293-301
Risultati: 1-7 |